SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly
LLY 1,057+1.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Moonray6/3/2020 9:51:12 PM
1 Recommendation

Recommended By
Lance Bredvold

   of 642
 
More: Eli Lilly Leaps Past Regeneron's COVID-19 Treatment Candidate

In the race to develop an effective new coronavirus treatment,
one of the West Coast's premier biotechnology companies just
got lapped by the oldest pharmaceutical giant in the Midwest

New coronavirus treatments are racing along the development
timeline so quickly that it's hard to tell who's in the lead from one
moment to the next. Until recently, Regeneron Pharmaceuticals
( NASDAQ:REGN) appeared to be furthest ahead with a new
COVID-19 treatment, but Eli Lilly ( NYSE:LLY) and the big
pharmaceutical company's new collaboration partner,
AbCellera, have already beaten Regeneron to an
important milestone.

Eli Lilly recently began dosing patients with LY-CoV555, an
experimental antibody that was isolated from one of the first
U.S. patients to recover from COVID-19. Regeneron's been
progressing at top speed with a similar program called
REGN-COV2, but patients aren't expected to begin
taking it until later this month.

More at: fool.com

o~~~ O
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News